BioCardia, Inc. 8K

BioCardia is presenting at the H.C. Wainwright conference to highlight regulatory and clinical progress for CardiAMP, Helix, and Heart3D, including planned submissions in Japan and the U.S.

BioCardia, Inc. announced that its President and CEO, Peter Altman, Ph.D., will present at the H.C. Wainwright 28th Annual Global Investment Conference, where he will update investors on the company’s regulatory and clinical progress for its CardiAMP autologous cell therapy program, including a planned Shonin pre-market submission to Japan’s PMDA targeted for the fourth quarter of 2026 and the ongoing U.S. CardiAMP HF II pivotal trial that may support PMA approval, as well as on the Helix transendocardial delivery platform for which a follow-on De Novo pre-submission is planned in the third quarter of 2026 and the Heart3D fusion imaging platform being advanced toward a potential FDA 510(k) submission, alongside broader business development activities and partnering opportunities.

Filing Facts

CIK

925741

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-030023

Alert Tier

5